Infectious disease
A University of Florida chemistry professor who fled the United States after falling under investigation for his ties to academic institutions in China has been at the forefront of developing a diagnostic test for the novel coronavirus in China.
As the world and biopharma grapple with developing vaccines and drugs against COVID-19, researchers are turning to a handful of drugs that show particular promise. Several of those drugs are by companies with offices or headquarters in the San Francisco Bay Area. Here’s a look.
The company did not know of her intention to leave the U.S. for China. They did not know she had been gone until the Chinese media reported the story. She was terminated by Biogen this week.
“What we have could be a very powerful weapon against these types of viral outbreaks or pandemics because it isn’t pathogen- or virus-specific and could be broadly relevant in these types of situations,” Gil Van Bokkelen, Ph.D., Athersys CEO, told BioSpace.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
As the number of diagnosed cases of COVID-19 continues to rise in the United States, Eli Lilly has partnered with the Indiana State Department of Health to accelerate testing for the virus in that state.
FujiFilm itself has not commented on the reports from China, The Guardian noted.
Epidemiologists believe COVID-19 will likely affect millions of people in the U.S. If early prevention efforts are not made Swine Flu Pandemic of 2009.
The company has initiated a late-stage trial assessing its rheumatoid arthritis drug Actemra in patients who have severe COVID-19 caused pneumonia.
The FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Pandemic, released Wednesday, are “a really good first step in ensuring that clinical trials continue with minimum disruption,” according to Jim Kremidas, executive director of the Association of Clinical Research Professionals (ACRP).
PRESS RELEASES